Desmopressin is approved in various forms, but these do not meet the paediatric need for precise, titratable and small doses.
Eton Pharma gets US patent covering its ET-600 product candidate’s proprietary formulation of desmopressin oral solution: Deer Park, Illinois Monday, February 10, 2025, 11:00 Hr ...
Product has patent protection through 2044 - - Expected to be listed in the U.S. Food and Drug Administration’s (FDA) Orange ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback